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This issue of Environmental Health
Perspectives Supplements includes papers
presented at the Conference on Beryllium-
related Diseases held November 8-10,
1994, at the National Institute of
Environmental Health Sciences, Research
Triangle Park, North Carolina. Beryllium
is the lightest ofall solid and chemically
stable substances and is used in some form
in the aerospace, nuclear, telecommunica-
tions, and computer industries, as well as
in ceramics, dental alloys, scientific equip-
ment, automotive parts, and tool and die
making. In the United States, it is esti-
mated that there are approximately 8000
plants with 30,000 workers who may be
potentially exposed to beryllium.
The potential hazards of exposure to
compounds of beryllium were first recog-
nized in the 1930s and 1940s with reports
ofpulmonary disease following exposure to
beryllium compounds (1-3). It was also in
the 1940s that fluorescent light manufac-
turers used beryllium in their lamp phos-
phors, which caused widespread poisoning
among workers and consumers until the
industry discontinued its use in 1949. The
first cases ofdelayed chemical pneumonitis
caused by beryllium were reported in 1946
(4). The cases reported were found among
former employees offluorescent-lamp plants
and established the clinical and morphologi-
cal characteristics ofberylliosis. It was not
until recent developments in molecular
genetics (5) and immunopathology (6) that
major advances in the understanding of
beryllium-related disease have taken place.
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The meeting highlighted several major
areas of concern regarding beryllium-
related diseases. Subjects discussed at this
conference included chronic beryllium dis-
ease and beryllium sensitization, the lym-
phocyte proliferation test, industrial
experience with workers exposed to beryl-
lium, industrial hygiene assessment of
beryllium-exposed workers, mechanisms in
chronic beryllium disease pathogenesis,
animal studies related to chronic beryllium
disease and cancer, carcinogenicity studies
ofworkers exposed to beryllium, occupa-
tional medical programs for current and
past exposed workers, future research needs
related to chronic beryllium disease, and
medical and ethical issues related to
chronic beryllium disease.
It is clear from the presentations and
discussions at this conference that there are
still many questions to be answered regard-
ing beryllium-related diseases. The discus-
sions concerning research needs were broad
and included the following five areas:
Toxicology. There is a need to continue
to develop animal models for chronic
beryllium disease. Gregory Finch of the
Inhalation Toxicology Research Institute/
Lovelace Research Institute gave an
overview talk titled "Animal Models of
Beryllium-induced Lung Disease," which is
included in the papers from this confer-
ence. Keith Meyer of the Department of
Medicine, Section of Pulmonary and
Critical Care Medicine ofthe University of
Wisconsin Medical School reported on his
investigations of the role of variations in
major histocompatibility (MHC) gene
expression in susceptibility to the granulo-
magenic effects ofberyllium. Dr. Meyer
discussed his attempt to induce granuloma-
tous lung inflammation in mouse strains
that varied in MHC class II antigen hap-
lotypes. He was able to induce granu-
lomatous lung inflammation in strain A
(H-2a MHC haplotype) mice via intra-
trachel installation ofberyllium sulfate.
His attempts to induce such inflamma-
tions in BALB/c (H-2dMHC haplotype)
nC57BL/6 (H-2b haplotype) mice were
unsuccessful. Dr. Meyer indicated that the
use ofthis model with manipulation ofthe
MHC complex or other genes important
in immune-medicated lung disease or the
use of transgenic mice with specific gene
deletions may give important insights into
mechanisms by which beryllium induces a
granulomatous inflammatory response in
the lung (7).
The overall consensus from the confer-
ence concerning this topic was that
research into the development of animal
models should include linking immuno-
pathology with the development of a
mouse model. Toxicology studies also need
to be designed to address the effect of
chronicversus acute exposures.
Biomarkers. The beryllium lymphocyte
proliferation test (BeLPT) must continue to
be developed. Emmanuel Ojo-Amaize of
Specialty Laboratories Inc. presented infor-
mation on an in vitro immunization system
used to generate beryllium-specific lympho-
cytes from healthy individuals who have
not been exposed to beryllium. Proliferative
responses of in vitro sensitized lymphocytes
were measured by [3H]thymidine uptake
after secondary stimulation with beryllium
salts. Analysis oflymphocytes from 52 indi-
viduals demonstrated that there is consid-
erable variation among individuals in their
capacities to be sensitized to beryllium salts
in vitro, i.e., individuals can be classified as
responders or nonresponders depending on
their levels of reactivity. It is unknown
whether the level ofresponse in vitro corre-
lates with the capacity to be sensitized to
beryllium dust in vivo (8).
The development ofthe BeLPT should
include cooperation between laboratories
to better characterize and minimize sources
of interlaboratory variability. There is also
a need to obtain enough data to make a
determination ofwhen the BeLPT can
move from an experimental test to a clini-
cal tool. This will require that a scheme be
developed for proficiency testing, the estab-
lishment ofstable cell clones, and adequate
quality control. There also needs to be con-
tinued basic cellular and molecular biology
research to identify additional biomarkers
for beryllium-related diseases.
Primary Prevention. There is a need
to develop adequate exposure assessment
data, which will be critical for the interpre-
tation of current epidemiology studies.
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There is also the need for investigators to
better understand the chemical properties
ofthe beryllium oxides versus other alloys
and the physical properties of their res-
pirable aerosols versus total particulates.
Exposure control is also an important
area for further research. Investigations
into the effect of excursions versus work
performance and conduct are needed.
Worker-based methods to further reduce
exposure, including personal sampling and
real-time monitoring investigations, also
need to be conducted.
Secondary Prevention. Medical moni-
toring must continue and use data from
current screening efforts to develop con-
sensus guidelines for chest X-rays, BeLPTs,
etc. These guidelines should also address
whom to screen, how the screen should be
conducted, when the screens should be
done, etc.
Surveillance programs are also critical
to allow for the systematic collection of
data. A registry of beryllium-sensitized
individuals could be established that could
be a life-long monitoring program to
insure continuous medical follow-up and
serve as a resource for studies ofthe natural
history ofberyllium-related diseases.
Tertiary Prevention. Additional clini-
cal and longitudinal epidemiology studies
to investigate the natural history of beryl-
lium-related diseases are needed. The clini-
cal studies should ask questions to address
the basic biology of the diseases as well as
their natural history.
It was felt that the priorities for the
research should first address the natural
history ofberyllium-related diseases, closely
followed by medical screening and surveil-
lance guidelines, and exposure assessment
and control.
This conference, as is evident in the
papers that follow, was able to bring
together investigators conducting research
on beryllium-related diseases and provide a
forum for the discussion of some of the
exciting recent advances in understanding
chronic beryllium disease. I thank all those
individuals who participated in the confer-
ence. I especially thank Rick Hornung,
Peter Infante, and Paul Wambach, whose
planning, suggestions, and organization
were instrumental in making the confer-
ence a success. A special thanks goes to
Merril Eisenbud, who originally proposed
the idea for this conference and was very
helpful in the development ofthe final pro-
gram. I am also deeply indebted to the
Joyce Daye for her hard work in adminis-
tratively coordination of all the speakers
and clerical assistance in the preparation of
these proceedings.
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